Primary aldosteronism: Rare bird or common cause of secondary hypertension?

Current Hypertension Reports

Volumn 3, Issue 3, 2001, Pages 230-239

  Stowasser, Michael ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; RENIN;

GENETICS; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; METABOLISM; REVIEW;

HUMANS; HYPERALDOSTERONISM; HYPERTENSION; RENIN;

EID: 0035379572     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-001-0045-3     Document Type: Article

References (62)

1. Conn JW: Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955, 45:6-17.
2. Gordon RD, Stowasser M, Klemm S.A., Tunny TJ: Primary aldosteronism and other forms of mineralocorticoid hypertension. In Textbook of Hypertension. Edited by Swales JD. London: Blackwell Scientific; 1994:865-892.
3. Young WF Jr: Primary aldosteronism: a common and curable form of hypertension. Cardiol Rev 1999, 7:207-214.
4. Lim PO, Dow E, Brennan G, et al.: High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 2000, 14:311-315.
5. Rayner BL, Opie LH, Davidson JS: The aldosterone/renin ratio as a screening test for primary aldosteronism. S Afr Med J 2000, 90:394-400.
6. Fardella CE, Mosso L, Gomez-Sanchez C, et al.: Primary aldosteronism in essential hypertensives: prevalence, biochemical profile and molecular biology. J Clin Endocrinol Metab 2000, 85:1863-1867.
7. Conn JW: Plasma renin activity in primary aldosteronism. Importance in differential diagnosis and in research of essential hypertension. JAMA 1964, 190:222-225.
8. Brown JJ, Davies DL, Lever A.F., Robertson JIS: Variations in plasma renin concentration in several physiological and pathological states. Can Med Assoc J 1964, 90:201-206.
9. Shamma AH, Goddard JW, Sommers SC: Study of adrenal status in hypertension. J Chronic Dis 1958, 8:587-595.
10. Conn JW: The evolution of primary aldosteronism: 1954-1967. Harvey Lect 1968, 62:257-291.
11. Conn JW, Rovner DR, Cohen E.L., et al.: Preoperative diagnosis of primary aldosteronism. Including a comparison of operative findings and preoperative tumour localization by adrenal phlebography. Arch Intern Med 1969, 123:113-123.
12. Gordon RD, Stowasser M, Tunny T.J., et al.: Clinical and pathological diversity of primary aldosteronism including a new familial variety. Clin Exp Pharmacol Physiol 1991, 18:283-286.
13. McKenna TJ, Sequeira SJ, Heffernan A, et al: Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary aldosteronism. J Clin Endocrinol Metab 1991, 73:952-957.
14. Kaplan NM: Commentary on the incidence of primary aldosteronism. Current estimations based on objective data. Arch Intern Med 1969, 123:152-155.
15. Laragh JH, Sealey JE, Sommers SC: Patterns of adrenal secretion and urinary excretion of aldosterone and plasma renin activity in normal and hypertensive subjects. Circ Res 1966, 18:158-174.
16. Fishman LM, Küchel O, Liddle G.W., et al.: Incidence of primary aldosteronism uncomplicated "essential" hypertension. JAMA 1968, 205:497-502.
17. Lund JO, Nielsen D, Giese J: Prevalence of primary aldosteronism. Acta Med Scand 1981, 646(suppl):54-57.
18. Berglund G, Andersson O, Wilhelmsen L: Prevalence of primary and secondary hypertension: studies in a random population. Br Med J 1976, 2:554-556.
19. Beevers DG, Nelson CS, Padfield P.L., et al.: The prevalence of hypertension in an unselected population, and the frequency of abnormalities of potassium, angiotensin II and aldosterone in hypertensive subjects. Acta Clin Belg 1974, 29:276-280.
20. Anderson GS, Toftdahl DB, Lund J.O., et al.: The incidence rate of phaeochromocytoma and Conns syndrome in Denmark, 1977-1981. J Hum Hypertens 1988, 2:187-189.
21. Crane MG, Harris JJ: Effect of aging on renin activity and aldosterone excretion. J Lab Clin Med 1976, 87:947-959.
22. Brunner HR, Laragh JH, Baer L, et al: Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972, 286:441-449.
23. Hiramatsu K, Yamada T, Yukimura Y., et al.: A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Arch Intern Med 1981, 141:1589-1593.
24. Gordon RD: Primary aldosteronism. J Endocrinol Invest 1995, 18:495-511.
25. Brown MJ, Hopper RV: Calcium-channel blockade can mask the diagnosis of Conn's syndrome. Postgrad Med J 1999, 75:235-236.
26. Lins PE, Adamson U: Plasma aldosterone-plasma renin activity ratio: a simple test to identify patients with primary aldosteronism. Acta Endocrinol 1986, 113:564-569.
27. Hamlet SM, Tunny TJ, Woodland E, Gordon RD: Is aldosterone/ renin ratio useful to screen a hypertensive population for primary aldosteronism? Clin Exp Pharmacol Physiol 1985, 12:249-252.
28. Stowasser M, Gordon RD: Prevalence and diagnostic workup of primary aldosteronism. Nephrology 2001, In press.
29. Gordon RD, Stowasser M, Tunny T.J., et al.: High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994, 21: 315-318.
30. Gordon RD, Ziezak MD, Tunny T.J., et al.: Evidence that primary aldosteronism may not be uncommon - twelve percent incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 1993, 20:296-298.
31. Lim PO, Rodgers P, Cardale K., et al.: Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet 1999, 353:40.
32. Lim PO, Jung RT, MacDonald TM: Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br J Clin Pharmacol 1999, 48:756-760.
33. Anwar AY, White WB, Mansoor GA, Tendler BE: Hyperaldoster-onism is a common cause of secondary hypertension missed by primary care physicians and associated with normokalemia [abstract]. Am J Hypertens 1998, 11: 199A.
34. Nishikawa T, Omura M: Clinical characteristics of primary aldosteronism: its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital. Biomed Pharmacother 2000, 54(Suppl 1):83s-85s.
35. Rossi G.P., Rossi E, Pavan E., et al.: Screening for primary aldosteronism with a logistic multivariate discriminant analysis. Clin Endocrinol 1998, 49:713-723.
36. Loh K-C, Koay E.S., Khaw M-C, et al.: Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000, 85:2854-2859.
37. Stowasser M, Taylor WL, Huggard PJ, et al.: Biochemical evidence of aldosterone overproduction and abnormal regulation in normotensive individuals with familial hyper-aldosteronism type I. J Clin Endocrinol Metab 1999, 84:4031-4036.
38. Stowasser M, Gordon RD: Primary aldosteronism: learning from the study of familial varieties. J Hypertens 2000, 18:1165-1176.
39. Lifton R.P., Dluhy RG, Powers M, et al: A chimaeric 11b-hydroxylase/ aldosterone synthase gene causes glucocorti-coid-remediable aldosteronism and human hypertension. Nature 1992, 355:262-265.
40. Jonsson JR, Klemm SA, Tunny T.J., et al.: A new genetic test for Familial Hyperaldosteronism Type I aids in the detection of curable hypertension. Biochem Biophys Res Comm 1995, 207:565-571.
41. Mulatero P, Veglio F, Pilon C., et al.: Diagnosis of glucocorticoid- remediable aldosteronism in primary aldosteronism: aldoster-one response to dexamethasone and long polymerase chain reaction for chimeric gene. J Clin Endocrinol Metab 1998, 83:2573-2575.
42. McAlister FA, Lewanczuk RZ: Primary hyperaldosteronism and adrenal incidentaloma: an argument for physiological testing before adrenalectomy. Can J Surg 1998, 41: 299-305.
43. Gordon RD, Gomez-Sanchez CE, Hamlet S.M., et al.: Angiotensin-responsive aldosterone-producing adenoma masquerades as idiopathic hyperaldosteronism (IHA: adrenal hyperplasia) or low-renin essential hypertension. J Hypertens 1987, 5(Suppl 5):S103-S106.
44. Ulick S, Chu MD: Hypersecretion of a new corticosteroid, 18-hydroxycortisol in two types of adrenocortical hypertension. Clin Exp Hypertens 1982, A4:1771-1777.
45. Stowasser M, Gartside MG, Gordon RD: A PCR-based method of screening individuals of all ages, from neonates to the elderly, for Familial Hyperaldosteronism Type I. Aust NZ J Med 1997, 27:685-690.
46. Fallo F, Veglio F, Mulatero P., et al.: Genetic studies in familial aldosteronism not suppressible by dexamethasone. J Endocrinol Genet 2000, 1:159-164.
47. Takeda Y, Furukawa K, Inaba S., et al.: Genetic analysis of aldosterone synthase in patients with idiopathic hyperaldos-teronism. J Clin Endocrinol Metab 1999, 84:1633-1637.
48. Hampf M, Widimsky J, Bernhardt R: Aldosterone synthase gene in patients suffering from hyperaldosteronism. Endo-crinol Res 1998, 24:877-880.
49. Davies E, Holloway CD, Ingram M.C., et al.: Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2. Hypertension 1999, 33:703-707.
50. Davies E: Variation at the aldosterone synthase gene locus (CYP11B2) in hypertension [abstract]. Paper presented at Cardiovascular Endocrinology and Metabolism, a Satellite Meeting to the International Congress of Endocrinology's Fourth Annual Meeting of the Society for Cardiovascular Endocrinology and Metabolism. October 27-29, 2000. Palm Grove, Queensland, Australia.
51. Curnow KM, Mulatero P, Emeric-Blanchouin N, et al.: The amino acid substitutions Ser288Gly and Val320Ala convert the cortisol producing enzyme, CYP11B1, into an aldosterone producing enzyme. Nat Struct Biol 1997, 4:32-35.
52. Pilon C, Mulatero P, Barzon L., et al.: Mutations in CYP11B1 gene converting 11b-hydroxylase into an aldosterone-producing enzyme are not present in aldosterone-producing adenomas. J Clin Endocrinol Metab 1999, 84:4228-4231.
53. Klemm SA, Ballantine DM, Tunny T.J., et al.: PCR-SSCP analysis of the angiotensin II type 1 receptor gene in patients with aldosterone-producing adenomas. Clin Exp Pharmacol Physiol 1995, 22:457-459.
54. Davies E, Bonnardeaux A, Plouin P-F, et al.: Somatic mutations of the angiotensin II (AT1) receptor gene are not present in aldosterone-producing adenoma. J Clin Endocrinol Metab 1997, 82:611-615.
55. Ballantine DM, Klemm SA, Tunny T.J., et al.: PCR-SSCP analysis of the p53 gene in tumours of the adrenal gland. Clin Exp Pharmacol Physiol 1996, 23:582-583.
56. Iida A, Blake K, Tunny T., et al.: Allelic losses on chromosome 11q13 in aldosterone-producing adrenal tumors. Genes Chromosomes Cancer 1995, 12:73-75.
57. Gordon RD, Gartside M, Tunny T.J., Stowasser M: Different allelic patterns at chromosome 11q13 in paired aldosterone-producing tumours and blood DNA. Clin Exp Pharmacol Physiol 1996, 23:594-596.
58. Torpy DJ, Gordon RD, Stratakis CA: Linkage analysis of familial hyperaldosteronism type II - absence of linkage of the gene encoding the angiotensin II receptor type 1. J Clin Endocrinol Metab 1998, 83:1046.
59. Torpy DJ, Gordon RD, Lin J-P, et al.: Familial hyperaldoster-onism type-II: description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene. J Clin Endocrinol Metab 1998, 83:3214-3218.
60. Lafferty AR, Torpy DJ, Stowasser M, et al: A novel locus for low-renin hypertension: familial hyperaldosteronism type II maps to chromosome 7 (7p22). J Med Genet 2000, 37:831-835.
61. McKnight GS, Clegg CH, Uhler MD, et al.: Analysis of the cAMP-dependent protein kinase system using molecular genetic approaches. Recent Prog Horm Res 1988, 44:307-335.
62. Kirschner LS, Carney JA, Pack S.D., et al.: Mutations of the gene encoding the protein kinase A type 1 - a regulatory subunit in patients with the Carney complex. Nat Genet 2000, 26:89-92.